Good on you for posting something that actually relates to the...

Good on you for posting something that actually relates to the company’s operations. The most important component that shareholders should be focused on IMO are the clinical programs.

While I have no doubt the company will list on the NASDAQ it’s ludicrous to think this is the catalyst for a price rerate when all the sector specific stocks on that exchange are under pressure.

As you stated with OSA, a 10% reduction would be highly significant. That’s an exciting near term catalyst that so many shareholders have seemingly forgotten about. What is IHL worth if they achieve a 10% reduction in AHI with this trial? In my view it’s a potential takeover target when you consider the size of the OSA market globally.

GW Pharma. If you don’t know their history then do yourself a favour and look into it because it’s a very good data point in the sector and extremely relevant to IHL.